Efficacy and safety of adalimumab in ankylosing spondylitis

Aziza Mounach, Abdellah El MaghraouiRheumatology Department, Military Hospital Mohammed V, Rabat, MoroccoAbstract: Ankylosing spondylitis (AS) is the most common and most severe subtype of spondyloarthritis. It also may be an outcome of any of the other spondyloarthritis subtypes. AS preferentially...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mounach A, El Maghraoui A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/4431ef900ec048c58a43f06f6e1098e7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4431ef900ec048c58a43f06f6e1098e7
record_format	dspace
spelling	oai:doaj.org-article:4431ef900ec048c58a43f06f6e1098e72021-12-02T00:14:02ZEfficacy and safety of adalimumab in ankylosing spondylitis1179-156Xhttps://doaj.org/article/4431ef900ec048c58a43f06f6e1098e72014-08-01T00:00:00Zhttp://www.dovepress.com/efficacy-and-safety-of-adalimumab-in-ankylosing-spondylitis-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156X Aziza Mounach, Abdellah El MaghraouiRheumatology Department, Military Hospital Mohammed V, Rabat, MoroccoAbstract: Ankylosing spondylitis (AS) is the most common and most severe subtype of spondyloarthritis. It also may be an outcome of any of the other spondyloarthritis subtypes. AS preferentially affects the sacroiliac joints and the tip of the column, with a tendency to later ankylosis. Peripheral joints, enthesis, and other extra-articular involvement may be observed. Tumor necrosis factor (TNF) inhibitors are now well-established, effective drugs in the treatment of AS symptoms. Adalimumab, which is a fully human monoclonal antibody that binds to and neutralizes TNF, has demonstrated efficacy in treating AS symptoms, including axial involvement, peripheral arthritis, enthesitis, uveitis, gut involvement, and psoriasis. Furthermore, adalimumab has showed an overall acceptable safety profile. In this paper, we review the efficacy and safety profile of adalimumab in the treatment of AS, and discuss its differences from the other anti-TNF drugs reported in the literature.Keywords: ankylosing spondylitis, spondyloarthritis, adalimumab, tumor necrosis factor-αMounach AEl Maghraoui ADove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2014, Iss default, Pp 83-90 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Mounach A El Maghraoui A Efficacy and safety of adalimumab in ankylosing spondylitis
description	Aziza Mounach, Abdellah El MaghraouiRheumatology Department, Military Hospital Mohammed V, Rabat, MoroccoAbstract: Ankylosing spondylitis (AS) is the most common and most severe subtype of spondyloarthritis. It also may be an outcome of any of the other spondyloarthritis subtypes. AS preferentially affects the sacroiliac joints and the tip of the column, with a tendency to later ankylosis. Peripheral joints, enthesis, and other extra-articular involvement may be observed. Tumor necrosis factor (TNF) inhibitors are now well-established, effective drugs in the treatment of AS symptoms. Adalimumab, which is a fully human monoclonal antibody that binds to and neutralizes TNF, has demonstrated efficacy in treating AS symptoms, including axial involvement, peripheral arthritis, enthesitis, uveitis, gut involvement, and psoriasis. Furthermore, adalimumab has showed an overall acceptable safety profile. In this paper, we review the efficacy and safety profile of adalimumab in the treatment of AS, and discuss its differences from the other anti-TNF drugs reported in the literature.Keywords: ankylosing spondylitis, spondyloarthritis, adalimumab, tumor necrosis factor-α
format	article
author	Mounach A El Maghraoui A
author_facet	Mounach A El Maghraoui A
author_sort	Mounach A
title	Efficacy and safety of adalimumab in ankylosing spondylitis
title_short	Efficacy and safety of adalimumab in ankylosing spondylitis
title_full	Efficacy and safety of adalimumab in ankylosing spondylitis
title_fullStr	Efficacy and safety of adalimumab in ankylosing spondylitis
title_full_unstemmed	Efficacy and safety of adalimumab in ankylosing spondylitis
title_sort	efficacy and safety of adalimumab in ankylosing spondylitis
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/4431ef900ec048c58a43f06f6e1098e7
work_keys_str_mv	AT mounacha efficacyandsafetyofadalimumabinankylosingspondylitis AT elmaghraouia efficacyandsafetyofadalimumabinankylosingspondylitis
_version_	1718403861349138432

Efficacy and safety of adalimumab in ankylosing spondylitis

Ejemplares similares